Drug intelligence / Profile preview

DNS 10820

Development stage: Preclinical
Lead developer: Adienne S.r.l. S.U.
Modality: Small Molecules

Overview

DNS 10820 is a small molecule indole derivative being developed by Adienne, an Italian pharmaceutical company. It belongs to a family of indolic derivatives involved in tryptophan metabolism and is intended for the treatment of immune dysreactive disorders, including various inflammatory and infectious diseases. Preclinical in vivo efficacy studies have yielded encouraging results, and the compound is currently undergoing active development to modulate immune responses through metabolic pathways related to tryptophan.

Beyond the preview

Go deeper on DNS 10820.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNS 10820.

Explore the full profile